Colgate Palmolive CO Form 4 insider transactions

Colgate-Palmolive Company Director Brian Newman acquired 208 shares of common stock on July 1, 2025, by deferring a portion of his annual cash retainer into a stock unit account.

Colgate-Palmolive Company Director John P. Bilbrey acquired 264 shares of common stock at $89.91 per share through a deferred compensation plan.

Colgate-Palmolive Company's COO, Americas, Shane Grant, was granted 90,000 shares of common stock as a restricted stock unit award.

Sally Massey, Chief Human Resources Officer at Colgate-Palmolive, reported selling 2,250 shares of common stock on May 15, 2025.

Director Kimberly A. Nelson received a stock grant and option award from Colgate-Palmolive on May 12, 2025, according to a Form 4 filing with the SEC.

Director Lorrie M Norrington reports receiving a stock grant and stock option grant from Colgate-Palmolive on May 12, 2025.

Director Brian Newman reports acquisition of stock and stock options from Colgate-Palmolive's incentive compensation plan.

Director Martina Hundmejean reports acquisition of stock and stock options in Colgate-Palmolive under the company's incentive compensation plan.

Director Lisa Edwards reports receiving an annual stock grant and stock option award from Colgate-Palmolive on May 12, 2025.

Director Martin Harris acquired 1,514 shares of common stock and options to purchase 2,272 shares of common stock from Colgate-Palmolive on May 12, 2025, as part of the company's incentive compensation plan.

Director Steven A. Cahillane reports receiving stock and option grants from Colgate-Palmolive on May 12, 2025.

Director John T. Cahill received a stock grant of 2,019 shares and stock options for 2,272 shares of Colgate-Palmolive common stock on May 12, 2025.

Director John P. Bilbrey reports acquisition of stock and options in Colgate-Palmolive through an annual director grant.

Director Brian Newman reports acquiring and disposing of Colgate-Palmolive stock, including shares acquired through a deferred compensation plan and shares held by a family trust.

Director Lorrie M Norrington acquired 258 shares of Colgate-Palmolive common stock at $91.99 per share on April 1, 2025, through a deferred compensation plan.

John P. Bilbrey, a director of Colgate-Palmolive, acquired 231 shares of common stock at a price of $91.99 on April 1, 2025, through a deferred compensation plan.

Sally Massey, Chief Human Resources Officer of Colgate-Palmolive, sold 8,000 shares of common stock at an average price of $92.019 on February 25, 2025.

Colgate-Palmolive's CEO, Noel Wallace, reported the vesting of performance-based restricted stock units and the subsequent withholding of shares for tax obligations.

Panagiotis Tsourapas, Group President, Europe & Developing Markets at Colgate-Palmolive, reports acquisition and disposal of company stock related to vesting of performance-based restricted stock units and associated tax obligations.

Chief Financial Officer of Colgate-Palmolive, Stanley Sutula III, reports acquisition and disposal of company stock related to vesting of performance-based restricted stock units and tax obligations.

Prabha Parameswaran, Group President of Growth & Strategy at Colgate-Palmolive, reports the vesting of performance-based restricted stock units and related tax withholding.

Sally Massey, Chief Human Resources Officer at Colgate-Palmolive, reports the vesting of restricted stock units and related tax withholding.

Gregory Malcolm, EVP and Controller at Colgate-Palmolive, reports acquisition of shares through vesting of restricted stock units and disposition of shares for tax liability.

Jennifer Daniels, CLO and Secretary of Colgate-Palmolive, reports acquisition of shares through vesting of restricted stock units and disposition of shares for tax liability.

Director John P. Bilbrey acquired 228 shares of Colgate-Palmolive common stock at $93.18 per share on January 2, 2025, through a deferred compensation plan.

Director Brian Newman acquired 201 shares of Colgate-Palmolive stock at $93.18 per share on January 2, 2025, increasing his direct holdings to 2,388 shares.

Director Lorrie M. Norrington acquired 281 shares of Colgate-Palmolive common stock at $93.18 per share on January 2, 2025, according to a Form 4 filing.

Panagiotis Tsourapas, a Group President at Colgate-Palmolive, reported a transaction involving the withholding of 168 shares for tax obligations.

Colgate-Palmolive's Chief Financial Officer, Stanley J. Sutula III, sold 252 shares of common stock to cover tax liabilities related to previously granted restricted stock units.

Colgate-Palmolive's CEO, Noel Wallace, disposed of 954 shares of common stock to cover Medicare and income tax liabilities related to previously granted restricted stock units.